The FDA has issued a warning letter to Houston-based Empower Clinic Services LLC, doing business as Empower Pharmacy, over the compounding of GLP-1 drug products under insanitary conditions that the agency said could result in contamination with what it described as “filth.” The letter, dated September 18, 2026, also alleges that the pharmacy’s compounded tirzepatide and semaglutide products “appear to be essentially copies” of FDA-approved drugs.
The action is significant because it represents the first explicit FDA enforcement move defining when pharmacy compounding crosses into illegal mass-copying of patented drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. The case has direct implications for telehealth platforms and the broader 503A compounding industry that has grown around GLP-1 demand.
What happened
FDA inspectors found that Empower Pharmacy was compounding tirzepatide and semaglutide products that the agency said appear to be essentially copies of FDA-approved products, including Mounjaro, Zepbound, Ozempic, and Wegovy. Under Section 503A, compounded drugs that are essentially copies of approved products do not qualify for the compounding exemptions that allow pharmacies to produce tailored medications without going through the full drug approval process.
The FDA also documented repeated verbatim prescriber determinations across many records, suggesting they may have been pre-generated. The agency further cited insanitary conditions at the Houston facility that could lead to contamination.
The FDA gave Empower 15 working days to respond in writing with steps to correct the violations. According to reporting, the company still listed tirzepatide and semaglutide on its website as of September 24.
Why it matters
This warning letter draws a clearer line on a question the compounding industry has faced throughout the GLP-1 boom: when does pharmacy compounding stop being legitimate customization and start becoming unauthorized production of copycat versions of patented drugs?
For 503A compounding pharmacies, the FDA’s reasoning signals sharper scrutiny of volume-driven compounding models and prescriber-workflow practices that may not meet the statutory requirements for individualized patient care.
For telehealth platforms that partner with 503A pharmacies, the enforcement action puts prescriber determination practices under a spotlight. The FDA’s concern about repeated verbatim determinations suggests regulators are looking beyond the pharmacy and into how prescriptions are generated.
For GLP-1 consumers who have turned to compounded alternatives for lower-cost access, the case could disrupt supply if more pharmacies face similar enforcement or voluntarily pull products.
What to watch next
- Whether Empower Pharmacy responds within the 15-working-day window and what corrective actions it proposes.
- Whether the pharmacy removes tirzepatide and semaglutide from its product listings.
- Whether FDA issues similar warning letters to other 503A pharmacies compounding GLP-1 products.
- How telehealth platforms adjust prescriber workflows in response to the FDA’s concerns about pre-generated determinations.
Sources
Industry information only. Not medical or legal advice.
